National Science and Technology Development Agency (NSTDA), Ministry of Higher Education, Science, Research and Innovation (NHS), and Mahidol University. Together with Chulalongkorn University, Kasetsart University, and other allied agencies both domestically and abroad. worked together to develop a malaria drug that is effective against drug-resistant germs called “Antifolate” is a work that started from basic research until it became a drug called “P218”. In the next step, it will be developed until it can be registered as a drug formula. To produce and use in prevention and treatment This will be the first antimalarial drug that comes from the complete research and development of Thai people. In the first cooperation agreement, NSTDA will work with Mahidol University, which has the ability and track record in developing drugs for registration and entering the market for a long time. This cooperation will help Thailand have drug security. Help developing countries gain access to quality, low-cost antimalarial drugs. and help Thailand get closer to its goal of eliminating malaria from the country.
Professor Emeritus Dr. Yongyut Yuttawong, senior expert on malaria in Thailand, NSTDA, said malaria is still a big problem in the world. It kills more than 600,000 people a year. Thailand also faces this problem. The fighting in neighboring countries has led to a worrying increase in the number of patients. Treatment is difficult because the infection is often resistant to drugs. Therefore, it is a matter that must be found to solve the problem. By designing medicines that will work effectively Researchers at the National Center for Genetic Engineering and Biotechnology (Biotech), NSTDA, have collaborated with various partner agencies both domestically and abroad to carry out research on malaria medicines for more than 30 years. The research team Protein-ligand engineering and molecular biology The Medical Molecular Biotechnology Research Group, BIOTECH, has been studying the structure of a target protein called DHFR, providing an understanding of changes in protein structure that cause drug resistance. Therefore, this knowledge has been used as a goal for drug development in collaboration with researchers from many countries around the world. Until it turned out to be the prototype antimalarial drug P218 that was published in 2013, which is the first antimalarial substance designed and synthesized by Thai researchers.
“The cooperation in pushing for the malaria drug P218 to become the first new drug from developing countries between Biotech, NSTDA and Mahidol will jointly conduct research and development to test the toxicity of P218 in animals. Experiment to test the efficacy of P218 at the clinical level. To predict the appropriate dose of P218 for effective treatment of malaria. By supporting resources, exchanging, and enhancing knowledge, experience, and academic information together efficiently. along with collaborating with other agencies including Chulalongkorn University To further develop antimalarial formulas into pharmaceuticals and health products with international standards. This will be expanded to the commercial production stage in the future. To support the production of antimalarial drugs that can actually be used In the form of cheap medicine Reaching the majority of patients who are poor This is an important step in moving forward with strong research along with partner agencies. To promote the availability of antimalarial products for developing countries. It is considered the first time in the world. by a team of researchers from Thailand”
Dr. Somboon Sahasitthiwat, Deputy Director of NSTDA, said that the cooperation between Biotech, NSTDA and Mahidol University It will help expand the results and develop a platform for finding and predicting the appropriate dose of P218 for treating malaria. and develop antimalarial drugs Toward pharmaceuticals and health products with international standards To expand the results into the next commercial production step. It is considered a collaboration between organizations under the Ministry of Natural Resources and Environment in using science. Technology and innovation Raise the level of the medical and public health industry in Thailand In line with the government’s policy that aims to drive the BCG economy and in line with the policy. “Good research-innovation meets needs” and “focuses on important issues of the country” of the Ministry of Natural Resources and Environment under the leadership of Ms. Supamas Issaraphakdee, Minister of Natural Resources and Environment, with the goal of building the potential to push P218 medicine towards It is the first new drug of Thailand and developing countries in the world to be successful.
Professor Dr. Banjong Mahaisavariya, President of Mahidol University, said that Mahidol University Recognizing the potential of P218, the drug development platform “Mahidol University Drug Discovery & Development” or MU-DDD has been used to push P218 into a drug product in Thailand. The MU-DDD platform arises from costs. The university’s research strength in medical science has been accumulated for more than 50 years and has received funding from the Reinventing University project of the Ministry of Natural Resources and Environment since 2021. The highlight of the platform is Completeness of drug development potential, complete from upstream to downstream and connected to the strength of research in laboratory animals The ability to develop drug formulas in a form suitable for use in various populations such as children, adults, and the elderly, as well as the strength in human research of the medical faculty. All three faculties in Mahidol Making it the most complete drug development platform in Thailand.
“Currently, Mahidol University has been attending meetings and conducting research with the NSTDA biotech research team in developing the drug P218 for a period of time and has received clear directions in pushing the drug P218 into different stages. that are necessary according to Thai and international drug registration criteria Including starting to coordinate with the Food and Drug Administration (FDA), Ministry of Public Health. Initially, this is to inform the FDA about such efforts. It is anticipated that we may be able to prepare various information and conduct additional research in no more than 2 years, so that we can successfully enter the process of requesting registration for the drug P218,” the President of Mahidol University concluded.
Professor Dr. Banjong Mahaisavariya, President of Mahidol University, said that Mahidol University Recognizing the potential of P218, the drug development platform “Mahidol University Drug Discovery & Development” or MU-DDD has been used to push P218 into a drug product in Thailand. The MU-DDD platform arises from costs. The university’s research strength in medical science has been accumulated for more than 50 years and has received funding from the Reinventing University project of the Ministry of Natural Resources and Environment since 2021. The highlight of the platform is Completeness of drug development potential, complete from upstream to downstream and connected to the strength of research in laboratory animals The ability to develop drug formulas in a form suitable for use in various populations such as children, adults, and the elderly, as well as the strength in human research of the medical faculty. All three faculties in Mahidol Making it the most complete drug development platform in Thailand.
“Currently, Mahidol University has been attending meetings and conducting research with the NSTDA biotech research team in developing the drug P218 for a period of time and has received clear directions in pushing the drug P218 into different stages. that are necessary according to Thai and international drug registration criteria Including starting to coordinate with the Food and Drug Administration (FDA), Ministry of Public Health. Initially, this is to inform the FDA about such efforts. It is anticipated that we may be able to prepare various information and conduct additional research in no more than 2 years, so that we can successfully enter the process of requesting registration for the drug P218” …… President of Mahidol University closed. end
2023-12-13 15:33:00
#NSTDA #Mahidol #joins #hands #develop #antimalarial #drug #invented #developed #Thai #researchers #Enhance #countrys #drug #security
